Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pablo Vicente Torres-Ortega"'
Autor:
Pablo Vicente Torres-Ortega, Rubén Del Campo-Montoya, Daniel Plano, Jacobo Paredes, Javier Aldazabal, María-Rosario Luquin, Enrique Santamaría, Carmen Sanmartín, María J. Blanco-Prieto, Elisa Garbayo
Publikováno v:
Biomacromolecules. 23:4629-4644
The co-administration of glial cell line-derived neurotrophic factor (GDNF) and mesenchymal stem cells (MSCs) in hydrogels (HGs) has emerged as a powerful strategy to enhance the efficient integration of transplanted cells in Parkinson's disease (PD)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e03fd4240792c351df91201dd992ddc8
https://doi.org/10.1021/acs.biomac.2c00853
https://doi.org/10.1021/acs.biomac.2c00853
Autor:
Pablo Vicente Torres-Ortega, Laura Saludas, Jon Eneko Idoyaga, Carlos Rodríguez-Nogales, Elisa Garbayo, María José Blanco-Prieto
Publikováno v:
Nanoparticles for Brain Drug Delivery ISBN: 9781003119326
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0415ad42e796997a94fa4464d7d20f3f
https://doi.org/10.1201/9781003119326-8
https://doi.org/10.1201/9781003119326-8
Publikováno v:
Proceedings of The 1st International Electronic Conference on Pharmaceutics.
Introduction: Glial cell line-derived neurotrophic factor (GDNF) is a well-establish therapeutic agent for Parkinson’s disease (PD) 1. Its therapeutic potential, being a glycosylated protein, will largely depend on the possibility of administering
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1be36c060e7cae5b5bc89cdf1729acd
https://doi.org/10.3390/iecp2020-08799
https://doi.org/10.3390/iecp2020-08799
Autor:
Eduardo Ansorena, Elisa Garbayo, María J. Blanco-Prieto, Pablo Vicente Torres-Ortega, Cristian Smerdou, María Cristina Ballesteros-Briones, Eva Martisova
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 159
Human glial cell line-derived neurotrophic factor (hGDNF) is the most potent dopaminergic factor described so far, and it is therefore considered a promising drug for Parkinson's disease (PD) treatment. However, the production of therapeutic proteins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20066fb723494740de24964a311b730f
https://pubmed.ncbi.nlm.nih.gov/33482318
https://pubmed.ncbi.nlm.nih.gov/33482318
Autor:
Amira Sayed Hanafy, Elisa Garbayo, Pablo Vicente Torres-Ortega, Maria-Rosario Luquin, Gloria Martí-Andrés, Ivan Martinez-Valbuena, María J. Blanco-Prieto
Publikováno v:
Nanobiotechnology in Neurodegenerative Diseases ISBN: 9783030309299
Parkinson’s disease (PD) is a complex neurodegenerative disorder. It is characterized by a combination of motor and nonmotor symptoms that gradually appear as consequence of the selective loss of dopaminergic neurons in the substantia nigra pars co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34e5b02b2b45976cc21e3627b0084b7c
https://doi.org/10.1007/978-3-030-30930-5_7
https://doi.org/10.1007/978-3-030-30930-5_7
Autor:
Laura Saludas, Elisa Garbayo, María J. Blanco-Prieto, Pablo Vicente Torres-Ortega, Amira Sayed Hanafy
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 295
Current therapies for Parkinson's disease are symptomatic and unable to regenerate the brain tissue. In recent years, the therapeutic potential of a wide variety of neuroprotective and neuroregenerative molecules such as neurotrophic factors, antioxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf03342a5ac18ed34364aee742ef5c74
https://pubmed.ncbi.nlm.nih.gov/30579984
https://pubmed.ncbi.nlm.nih.gov/30579984